Observational data link hydroxychloroquine blood levels to modest ASCVD risk differences in SLE

Researchers at Yale measured HCQ blood concentrations and prescription refills in 248 patients (mean age 47) while calculating 10-year ASCVD risk via the AHA pooled cohort equation. Patients below therapeutic HCQ thresholds or with declining adherence showed absolute risk elevations just under 7% at baseline and nearly 6% at follow-up. The cohort design captured real-world exposure but could not isolate HCQ effects from unmeasured confounders such as disease activity or concurrent therapies.

Systemic lupus erythematosus already confers markedly elevated cardiovascular risk, with young women facing up to 50-fold higher myocardial infarction rates than peers. Hydroxychloroquine remains first-line therapy because prior observational and registry data associate consistent use with fewer flares and less organ damage. This study adds a quantitative signal that subtherapeutic levels track with higher short-term risk estimates, yet the absolute increments remain small in a relatively young population.

Because the analysis is observational, causation cannot be inferred; healthier behavior or milder disease may drive both better adherence and lower risk scores. No randomized comparison of level-guided versus fixed dosing exists. Next steps require prospective trials that randomize patients to therapeutic drug monitoring versus standard care and track actual ASCVD events rather than risk calculators over at least five years.

Health systems could test point-of-care HCQ assays coupled with adherence support programs, but implementation should await evidence that such interventions reduce clinical events without increasing polypharmacy.